Natalia Gulyaeva and Maria Sedykh of Hogan Lovells look at the main drivers of collaboration in the pharmaceutical sector and the legal issues to keep in mind when handling partnerships in Russia.
Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain.
India’s position on patenting genes borrows heavily from that of the US, but will the status quo change? Swarup Kumar of Remfry & Sagar reports.
To overcome a crowded patent market, a potential solution is to seek a declaration of obviousness, which has a basis in UK law stemming from Arrow Generics v Merck. Richard Roberts of Potter Clarkson reports.
The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.
With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.
The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker.
The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins.
Global companies are watching a pending life sciences patent case at the US Supreme Court because of its potential impact both within and outside US borders, as Sandra Kuzmich and Russell Garman of Frommer Lawrence & Haug explain.
In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson.